Follow CAP on Social Media

Listen to the CAP Podcast

With Infection Rates Surging in Countries That Have Relied Mostly on Chinese Vaccines, Officials May Be Trying to Change the Narrative

The debate over the effectiveness of Chinese COVID-19 vaccines in preventing infections may be entering a new stage as infection rates rise steadily in countries that have predominantly relied on jabs made by Sinopharm and Sinovac.

Critics argue that some Chinese vaccine phase 3 clinical trials have shown efficacy rates to be barely above 50%, as was the case with Sinovac in Brazil. They say that explains the resurgence of the virus in some countries, even though large percentages of these populations have received injections.

  • Get a daily email packed with the latest China-Africa news and analysis.
  • Read exclusive insights on the key trends shaping China-Africa relations.
  • Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.

China, Africa and the Global South... find out what’s happening.

Subscribe today for unlimited access.

What is The China-Africa Project?

Independent

The CAP is passionately independent, non-partisan and does not advocate for any country, company or culture.

News

A carefully curated selection of the day’s most important China-Africa stories. Updated 24 hours a day by human editors. No bots, no algorithms.

Analysis

Diverse, often unconventional insights from scholars, analysts, journalist and a variety of stakeholders in the China-Africa discourse.

Networking

A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.